Olfat, M <br/><br/>
Rituximab therapy has a rapid and durable response for refractory cytopenia in childhood-onset systemic lupus erythematosus.  [electronic resource] 

 -  Lupus  Aug 2015 
 - 966-72 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1477-0962 
<br/><br/><label>Standard No.: </label>10.1177/0961203315578764  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Agammaglobulinemia--drug therapy<br/>Age of Onset<br/>Anemia, Hemolytic, Autoimmune--blood<br/>Antirheumatic Agents--adverse effects<br/>B-Lymphocytes--immunology<br/>Child<br/>Cohort Studies<br/>Female<br/>Humans<br/>Immunoglobulins, Intravenous--therapeutic use<br/>Immunophenotyping<br/>Lupus Erythematosus, Systemic--blood<br/>Male<br/>Purpura, Thrombocytopenic, Idiopathic--blood<br/>Remission Induction<br/>Retrospective Studies<br/>Rituximab--adverse effects<br/>Treatment Outcome